The FDA Modernization Act 2.0 has triggered a new mindset for pharma, with Roche launching the Institute of Human Biology to create better models, and MSD collaborating with Inventia to bioprint 3D in vitro models to screen for neurodegenerative therapeutic candidates.

It has never been a more exciting time to bet on 3D tissue models as the future of drug development, as more and more complex in vitro models undergo validation. However, the big question of “ Are they going to be economically viable as a drug development tool, what is the return on investment for us, and how to do it at scale?” persists at the forefront of biopharma leaders’ thoughts.

Making its timely return to Boston this May, the 9th 3D Tissue Models Summit will enable you and your team to uncover best practices of complex in vitro model use across drug discovery and development through 23+ practical case studies. Join us to learn from and meet the ‘front-line’ experts optimizing and leveraging advanced 3D tissue models to confidently empower your own drug development workflows in a time-efficient and cost-effective way.

Event Link here.